OBJECTIVE: To study human papillomavirus type 16 in the aetiology of cervical carcinoma. DESIGN: Within a cohort of 18814 Finnish women followed up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. SUBJECTS: 72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. MAIN OUTCOME MEASURE: Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. RESULTS: After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P<0.001). CONCLUSION: This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.
OBJECTIVE: To study human papillomavirus type 16 in the aetiology of cervical carcinoma. DESIGN: Within a cohort of 18814 Finnish women followed up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. SUBJECTS: 72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. MAIN OUTCOME MEASURE: Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. RESULTS: After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P<0.001). CONCLUSION: This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.
Authors: M Lehtinen; I Rantala; R Aine; A Miettinen; S Laine; P Heinonen; K Teisala; R Punnonen; J Paavonen Journal: Eur J Clin Microbiol Date: 1986-10 Impact factor: 3.267
Authors: M Hakama; M Lehtinen; P Knekt; A Aromaa; P Leinikki; A Miettinen; J Paavonen; R Peto; L Teppo Journal: Am J Epidemiol Date: 1993-01-15 Impact factor: 4.897
Authors: M H Schiffman; H M Bauer; R N Hoover; A G Glass; D M Cadell; B B Rush; D R Scott; M E Sherman; R J Kurman; S Wacholder Journal: J Natl Cancer Inst Date: 1993-06-16 Impact factor: 13.506
Authors: J Dillner; P Lenner; M Lehtinen; C Eklund; P Heino; F Wiklund; G Hallmans; U Stendahl Journal: Cancer Res Date: 1994-01-01 Impact factor: 12.701
Authors: J Dillner; F Wiklund; P Lenner; C Eklund; V Frederiksson-Shanazarian; J T Schiller; M Hibma; G Hallmans; U Stendahl Journal: Int J Cancer Date: 1995-01-27 Impact factor: 7.396
Authors: B Nonnenmacher; N L Hubbert; R Kirnbauer; K V Shah; N Muñoz; F X Bosch; S de Sanjosé; R Viscidi; D R Lowy; J T Schiller Journal: J Infect Dis Date: 1995-07 Impact factor: 5.226
Authors: M Puolakkainen; E Hiltunen-Back; T Reunala; S Suhonen; P Lähteenmäki; M Lehtinen; J Paavonen Journal: J Clin Microbiol Date: 1998-06 Impact factor: 5.948